Impact of National Screening Programs on Down syndrome prevalence and outcomes
Acta Obstetricia et Gynecologica Scandinavica · 2026
DOI: 10.1111/aogs.70157 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Obstetricia et Gynecologica Scandinavica, 2026. Verfasst von Cecilie Bryn Nordklev und 5 weiteren Autor:innen. Beteiligte Einrichtung: Fetal Medicine Centre, Oslo University Hospital, Oslo, Norway. Hauptthemen laut MEDLINE: Down Syndrome, Prenatal Diagnosis. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Introduction
Over the past five decades, antenatal screening programs have evolved significantly, primarily through advancements in ultrasound technology and the shift from invasive to non‐invasive prenatal testing methods. This study aimed to evaluate the impact of these developments in prenatal screening for Down syndrome (DS) on the prevalence of live and stillbirths, as well as terminations of pregnancy (TOP) with DS. Material and Methods This population‐based registry study included all pregnancies in Norway from 1967 to 2021, with data on TOPs available from 1999. Information on DS pregnancies was obtained from the Medical Birth Registry of Norway. Logistic regression models were applied to evaluate time trends and maternal characteristics associated with TOP.
Results
Among 3 231 159 pregnancies, 4764 (0.147%) were affected by DS. The prevalence of DS pregnancies increased from 0.165% in 1999 to 0.251% in 2021. During this period, the proportion of TOP rose from 20% to 55%, while prenatal detection rates improved from 18% to 70%. Despite increased detection, the proportion of TOP following prenatal diagnosis remained stable at approximately 80%. The prevalence of live births with DS remained stable at approximately 0.106%, while the prevalence of stillbirths was around 0.008%. Maternal age, parity, country of birth, and region of residence were associated with TOP decisions. Mean gestational age at termination decreased from 17.5 to 15.7 weeks.
Conclusions
Over recent decades, prenatal detection and termination of DS pregnancies have increased. However, the proportion of women continuing pregnancies after a prenatal diagnosis and the prevalence of live‐ and stillbirths with DS have remained stable.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Fetal Medicine Centre, Oslo University Hospital, Oslo, Norway.
- Faculty of Medicine, University of Oslo, Oslo, Norway.
- Norwegian Research Centre for Women's Health, Oslo University Hospital, Oslo, Norway.
- The Cancer Registry of Norway, Norwegian Institute of Public Health, Oslo, Norway.
- Faculty of Health and Social Sciences, Western Norway University of Applied Sciences, Bergen, Norway.
- Department of Clinical Science, University of Bergen, Bergen, Norway.
ORCID-Profile: Cecilie Bryn Nordklev, Denise Reis Costa, Roy Miodini Nilsen, Siri Vangen, Vasilis Sitras
Zitieren
APA
Nordklev, C. B., Costa, D. R., Nilsen, R. M., Morken, N. H., Vangen, S., & Sitras, V. (2026). Impact of National Screening Programs on Down syndrome prevalence and outcomes. Acta Obstetricia et Gynecologica Scandinavica. https://doi.org/10.1111/aogs.70157
Vancouver
Nordklev CB, Costa DR, Nilsen RM, Morken NH, Vangen S, Sitras V. Impact of National Screening Programs on Down syndrome prevalence and outcomes. Acta Obstetricia et Gynecologica Scandinavica. 2026. doi:10.1111/aogs.70157
BibTeX
@article{Nordklev2026,
author = {Nordklev, Cecilie Bryn and Costa, Denise Reis and Nilsen, Roy Miodini and Morken, Nils-Halvdan and Vangen, Siri and Sitras, Vasilis},
title = {Impact of National Screening Programs on Down syndrome prevalence and outcomes},
journal = {Acta Obstetricia et Gynecologica Scandinavica},
year = {2026},
doi = {10.1111/aogs.70157}
}
EUVIMED